FUTURE OF HEALTHCARE

Athlete Training and Health Expands with New Facilities, Team Members

Athlete | September 27, 2022 | Read time : 04:00 min

Athlete Training

Whether for active adults or Olympians, Athlete Training and Health (ATH) encourages its athletes to strive for their own personal best. ATH is raising its own bar on community health and performance training once again, with the announcement of two new facilities in the Houston area and the addition of another world-renowned coach to its executive staff.

What we know is that evidence-led training allows everyone to benefit from the science behind the best in health and performance. Expanding and offering this world-class environment and approach will benefit athletes of all ages and abilities. We are pleased to collaborate with healthcare systems, professional sports teams, universities and school districts to continue pursuing a new level of health and performance training for many communities.”

Greg Centilli, chief operating officer for ATH and a recent addition to the growing ATH organization

Construction has begun on a new ATH sports medicine and human performance facility in Pearland. Located on the Memorial Hermann Pearland Hospital campus at 16100 South Freeway, the roughly 13K-square-foot facility will house unparalleled human performance expertise and opportunities to train in an adult fitness space, a professional sport-style weight room, and on indoor and outdoor turf fields. The facility, a collaboration between ATH, Memorial Hermann and UT Physicians Orthopedics, is expected to open fall 2023.

Also in the works is an ATH facility in Cypress, also in collaboration with Memorial Hermann. On the campus of Memorial Hermann Cypress Hospital at 27800 Highway 290, ATH will open and operate a roughly 13K-square-foot facility in 2024. At this location, student, collegiate, professional and adult athletes will find the expertise needed to up their game on their own performance.

“We are extremely pleased to welcome Professor Cronin to ATH. His science-based expertise and educational experience, alongside his international standing, will help educate investors and the general markets on the significance and industry importance of ATH-led initiatives,” said Centilli.

Cronin serves as professor of strength and conditioning at the Sports Performance Research Institute of New Zealand (SPRINZ) at Auckland University of Technology (AUT). His research interests are in human movement, particularly around strengthening of muscle, injury resistance, return to play and high-performance sports. Cronin’s research has been published in more than 400 peer-reviewed papers.

AUT and ATH have a long-standing history. Post-graduate fellows from AUT conduct research at ATH as part of a team involving coaches and select students, as well as collaborate on sport technology development.

“I know the organization well, and my research interests and expertise align well with ATH’s interest in sporting performance and allied health, so I’m very excited to be advising ATH about the latest science-based studies and learnings to support their people, programs and products,” Cronin said.

Celebrating Wins
While its clients celebrate personal victories, ATH celebrates industry wins. Readers of Living Magazine recently voted ATH the “2022 Best Health Club/Gym” winner in McKinney/Allen and in Katy/Fulshear via an annual award competition that allows readers to nominate and then vote for their favorite companies by category and market.

ATH also was honored to be named a “2022 Neighborhood Favorite” in NextDoor’s annual celebration of local businesses, and a finalist for “2022 Best Gym/Fitness Center in Houston” by readers of Houston Chronicle in an annual awards competition voted on by Houstonians.

“While it’s important for us to acknowledge the hard work of our coaches and staff who make awards like these possible, it’s our job to continuously raise the bar, so we consider this just the beginning,” noted Centilli. “We are excited about what we have accomplished and are even more excited for the developments ahead.”

Whether it’s losing the pandemic pounds, living in a healthier body, or even reaching the pinnacle of your sport, the certified, experienced sports performance experts at ATH have the expertise and a program tailored just for you.

ABOUT ATHLETE TRAINING AND HEALTH (ATH)
ATH is more than a gym. It’s a place of community, inspiration and results. ATH provides award-winning adult fitness and sports performance training for youth, collegiate and professional athletes. ATH utilizes best practices from human performance research to provide a world-class training environment for athletes and adults of all fitness levels collaborating with hospitals, professional sports teams, universities and school districts to set new standards for health and performance training. ATH invests heavily in the post-graduate education of its performance coaches, who in turn develop evidence-led training programs guaranteed to deliver sustainable results. ATH currently operates two training centers in the Houston metro area and one in Allen, north of DFW. 

Spotlight

Patient safety has always been at the heart of the movement to improve quality in health care. More than 30 years ago, the Harvard Medical Practice Study helped kick off the quality movement by demonstrating that many, if not most, instances of harm in hospitals were caused by system failures.

Spotlight

Patient safety has always been at the heart of the movement to improve quality in health care. More than 30 years ago, the Harvard Medical Practice Study helped kick off the quality movement by demonstrating that many, if not most, instances of harm in hospitals were caused by system failures.

Related News

HEALTHTECH SECURITY

Providers Now Have Free Access to Latest Diabetes Technology in One Place

Association of Diabetes Care & Education Specialists (ADCES) | October 14, 2022

All healthcare professionals caring for people with diabetes now have access to vital information about the latest diabetes technology in one place through the Association of Diabetes Care & Education Specialists' (ADCES) newly revamped danatech website. Launched in 2018, danatech has been updated and enhanced. ADCES now provides free danatech access to all healthcare professionals, from the nurse who is trying to determine if insurance will cover a prescription for a continuous glucose monitor (CGM) to the provider who wants to compare the various insulin pumps to the radiologist who wants to know whether a patient should remove their device before having an MRI. Site visitors can also access training and education on the devices, including many for continuing education (CE/CME) credit. Many of these offerings are free. "The number of people with diabetes is skyrocketing and there aren't nearly enough specialists to treat them all, healthcare professionals in multiple practice settings are caring for people with diabetes. But many are not familiar with the multitude of new technologies and devices available to those who need them the most. These technologies and devices generate the data that allows for effective care planning and danatech helps healthcare professionals get up to speed so they can collaborate with their patients most effectively to self-manage their diabetes." Leslie Kolb, DrPH, MBA. BSN, RN, chief science, practice and learning officer for ADCES The easy-to-navigate site includes information on apps and digital therapeutics designed to prevent, manage and/or treat diabetes and features CGM insurance lookup tool to determine whether a patient's insurance pays for a CGM prescription. Information for all brands of CGMs, insulin pumps and insulin/medicine delivery systems. Free and fee-based training and education for CE/CME on the various devices. Three certificate programs: Putting Continuous Glucose Monitoring (CGM) Into Practice, Connected Insulin Devices and The Art of Telehealth. "While some of these resources are available elsewhere, it's piecemeal, whereas danatech brings it all together," said Kolb. "For example, if a provider wants to compare insulin pumps to determine which would be best for a patient, they'd have to visit each of the manufacturer's websites individually. Now they don't."

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More

HEALTHTECH SECURITY

Henry Ford Health and the PINC AI™ Applied Sciences Team Lead Action to Advance Health Equity

Henry Ford Health | November 21, 2022

Henry Ford Innovations one of the nation's leading healthcare innovation programs, recently hosted the inaugural "Advancing Health Equity Through Innovation and Collaboration" event in partnership with the PINC AI™ Applied Sciences team, a leading provider of advanced analytics, technology solutions and clinical research support services to the life sciences industry. The initiative's purpose was to turn health equity conversations into action by taking measurable steps towards improving the health of millions. Participants included global leaders in life sciences, as well as Henry Ford Health innovators who are already implementing programs to address health disparities in groups who have been historically marginalized and underrepresented. "Part of innovating is looking for partners to expand successful test programs and develop new ones. Partnerships like the ones we're forging with these corporate partners will create a true impact in addressing health equity. We are thrilled to have the opportunity to share our findings with national leaders in the life sciences and pharmaceutical industries and chart a path forward to bring these solutions to help more people." Lisa Prasad, Henry Ford Health's Chief Innovation Officer and leader of Henry Ford Innovations The two-day event in late October included a presentation of case studies from successful Henry Ford Health programs, including community-based partnerships to increase health screenings. That program found that a lack of trust in institutions can deter people from getting preventative care and that using community partners for healthcare services can reduce barriers and increase access to care. Other case studies covered programs to improve hypertension in young African American men and reduce infant mortality among underserved populations. The unique action-focused event allowed leaders from Henry Ford Health, the PINC AI™ Applied Sciences team and collaborators from eight global life sciences companies to meet, connect and work together on ways to amplify and expand pilot programs. "The impactful work Henry Ford Health already has under way makes Detroit an ideal location to look for solutions to reduce health inequities across the country," said Denise Juliano, Life Sciences Group Vice President, PINC AI™ Applied Sciences. "PINC AI™ Applied Sciences partners with leaders in healthcare to improve health outcomes and advance equitable care for all people. This initiative was a great step forward to accelerate our efforts to address the challenges of health inequities that continue to persist." Because of Henry Ford Health's community connections and its long-standing work to improve diversity, equity, inclusion and justice (DEIJ), the health system is a leader in researching and tackling health disparities in Detroit. In 2021, Henry Ford launched a new initiative to improve the representation of African American people in cancer clinical trials. It was an important collaboration, especially considering that recent research shows 85 percent of participants in clinical trials are white. Another program supported by HFI provides medical mentorship and internship opportunities for Detroit-based high school students. Both initiatives serve as examples of the meaningful change health and life sciences organizations can affect together. "This initiative is an example of how Henry Ford's commitment to DEIJ extends beyond ideas and connects directly to action," said Ikenna Okereke, M.D., Henry Ford Health's Vice Chair of Surgery and Director of Thoracic Surgery. "Through Henry Ford's Department of Surgery High School Mentorship Program, I've seen firsthand how programs that work in other communities can grow for a larger impact. I'm excited to be a part of the next chapter in creating more programs and initiatives to address health disparities." Henry Ford Health and the PINC AI™ Applied Sciences team will now work with the summit's participating partners to strengthen and scale solutions to advance health equity. About Henry Ford Health Serving communities across Michigan and beyond, Henry Ford Health is committed to partnering with patients and members along their entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, health insurance, a full suite of home health offerings, virtual care, pharmacy, eye care and other healthcare retail. It is one of the nation's leading academic medical centers, recognized for clinical excellence in cancer care, cardiology and cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, and multi-organ transplants. Consistently ranked among the top five National Institutes of Health (NIH)-funded institutions in Michigan, Henry Ford Health engages in more than 2,000 research projects annually. Equally committed to educating the next generation of health professionals, Henry Ford Health trains more than 4,000 medical students, residents, and fellows every year across 50+ accredited programs. With more than 33,000 valued team members, Henry Ford Health is also among Michigan's largest and most diverse employers, including nearly 6,000 physicians and researchers from the Henry Ford Medical Group, Henry Ford Physician Network and Jackson Health Network. The health system is led by President and CEO Robert G. Riney and serves a growing number of customers across 250+ locations throughout Michigan including five acute care hospitals, two destination facilities for complex cancer and orthopedics and sports medicine care, three behavioral health facilities, primary care and urgent care centers. About the PINC AI™ Platform PINC AI™ is the technology and services platform of Premier Inc. With more than 20 years' worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 812 million hospital outpatient and clinic encounters and 131 million physician office visits, the PINC AI™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI™ offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI™ platform is also the data engine powering Premier's newest brands – Remitra™ and Contigo Health®.

Read More